Five years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by the FDA for certain ovarian cancers. Now the UK pharma is aiming to build ...

Currently, five PARP inhibitor drugs are running in clinical trials for approval. All have shown proof of concept success in germline BRCA mutation carriers. Furthermore, several combinations with ...

PARP inhibitors, such as olaparib, have demonstrated fantastic results for some men. However, not all men respond to this drug, and for those that do, their cancer eventually develops resistance.

The combination therapy approval from the US Food and Drug Administration (FDA ... biology and bringing a targeted therapy like a PARP inhibitor will hopefully move the needle.” ...

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments ... on several factors that scientists should keep in mind during the screening and drug development process. As ...

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer. The alliance is important for Tesaro, which is ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

The first wave of PARP inhibitors has improved outcomes in people with a variety of solid tumors. However, Idience has identified opportunities to improve the efficacy of existing drugs and ...

Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for ...

One important problem that may arise during PARP inhibitor treatment is the development of resistance. Even BRCA-deficient mouse tumors were reported to acquire resistance to PARP inhibitors.